INAB
In8bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Bearish Engulfing
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INAB
In8bio, Inc.
A clinical-stage biopharmaceutical company that focused on gamma-delta T cell product candidates for solid and liquid tumors
350 5th Avenue, Suite 5330 , New York, New York 10118
--
In8 bio, Inc., was incorporated in Bermuda on February 8, 2016. On May 7, 2018, the company was reincorporated into the United States in a transaction in which the company was transformed into a newly formed Delaware company, a clinical-stage biotechnology company focused on the discovery, development and commercialization of gamma-delta T cell candidates for solid and liquid tumors.
Company Financials
EPS
INAB has released its 2025 Q3 earnings. EPS was reported at -0.85, versus the expected -1.25, beating expectations. The chart below visualizes how INAB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
